Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

Lee S. Schwartzberg; Grace Wang; Bradley G. Somer; L. Johnetta Blakely; Benton M. Wheeler; Mark S. Walker; Edward J. Stepanski; Arthur C. Houts

doi:10.1016/j.clbc.2013.09.003

Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

Lee S. Schwartzberg, Grace Wang, Bradley G. Somer, L. Johnetta Blakely, Benton M. Wheeler, Mark S. Walker, Edward J. Stepanski, Arthur C. Houts

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Breast Cancer
Volume	14
DOIs	https://doi.org/10.1016/j.clbc.2013.09.003
State	Published - Jan 2 2014

Disciplines

Medicine and Health Sciences
Surgery

Access to Document

10.1016/j.clbc.2013.09.003License: Unspecified

Cite this

@article{a0e275551daa4f548f44e7167e18bbd5,

title = "Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.",

author = "Schwartzberg, \{Lee S.\} and Grace Wang and Somer, \{Bradley G.\} and Blakely, \{L. Johnetta\} and Wheeler, \{Benton M.\} and Walker, \{Mark S.\} and Stepanski, \{Edward J.\} and Houts, \{Arthur C.\}",

note = "Patients with ≤ 1 previous hormonal treatment in the metastatic setting received an injection fulvestrant loading dose 500 mg on day 1, 250 mg on days 15 and 29 followed by 250 mg every 28 days along with continuous oral capecitabine in divided doses.",

year = "2014",

month = jan,

day = "2",

doi = "10.1016/j.clbc.2013.09.003",

language = "American English",

volume = "14",

journal = "Clinical Breast Cancer",

}

TY - JOUR

T1 - Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

AU - Schwartzberg, Lee S.

AU - Wang, Grace

AU - Somer, Bradley G.

AU - Blakely, L. Johnetta

AU - Wheeler, Benton M.

AU - Walker, Mark S.

AU - Stepanski, Edward J.

AU - Houts, Arthur C.

N1 - Patients with ≤ 1 previous hormonal treatment in the metastatic setting received an injection fulvestrant loading dose 500 mg on day 1, 250 mg on days 15 and 29 followed by 250 mg every 28 days along with continuous oral capecitabine in divided doses.

PY - 2014/1/2

Y1 - 2014/1/2

UR - https://www.sciencedirect.com/science/article/pii/S1526820913002164

U2 - 10.1016/j.clbc.2013.09.003

DO - 10.1016/j.clbc.2013.09.003

M3 - Article

VL - 14

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

ER -

Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

Disciplines

Access to Document

Other files and links

Cite this